Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial-Reference-Cited by-同舟云学术

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

Published:2020-05 Issue:5 Volume:21 Page:645-654
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Trigo José,Subbiah Vivek,Besse Benjamin,Moreno Victor,López Rafael,Sala María Angeles,Peters Solange,Ponce Santiago,Fernández Cristian,Alfaro Vicente,Gómez Javier,Kahatt Carmen,Zeaiter Ali,Zaman Khalil,Boni Valentina,Arrondeau Jennifer,Martínez Maite,Delord Jean-Pierre,Awada Ahmad,Kristeleit Rebecca,Olmedo Maria Eugenia,Wannesson Luciano,Valdivia Javier,Rubio María Jesús,Anton Antonio,Sarantopoulos John,Chawla Sant P,Mosquera-Martinez Joaquín,D'Arcangelo Manolo,Santoro Armando,Villalobos Victor M,Sands Jacob,Paz-Ares Luis

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Früh;Ann Oncol,2013

2. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer;Horn;N Engl J Med,2018

3. Paz-Ares L, Chen Y, Reinmuth N, et al. Overall survival with durvalumab plus etoposide-platinum in first-line extensive-stage SCLC: results from the Caspian study. World Conference on Lung Cancer (IASLC); Barcelona, Spain; Sept 7–10, 2019 (abstr PL02.11).

4. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer;von Pawel;J Clin Oncol,1999

5. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer;von Pawel;J Clin Oncol,2001

Cited by 247 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenic cell stress and death in the treatment of cancer;Seminars in Cell & Developmental Biology;2024-03

2. Recent advances and future strategies in first-line treatment of ES-SCLC;European Journal of Cancer;2024-03

3. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases;Lung Cancer;2024-02

4. Chemical and microbial diversity of a tropical intertidal ascidian holobiont;Marine Environmental Research;2024-02

5. Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study;Pharmaceuticals;2024-01-30